Leerink Partners Upgrades Abbott Laboratories (NYSE:ABT) to "Outperform"

Abbott Laboratories logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Leerink Partners upgraded Abbott Laboratories to “outperform” from “market perform,” setting a $124 price target—about 18.7% above the share price cited in the article.
  • Analyst sentiment is broadly positive: MarketBeat reports a “Moderate Buy” consensus and an average price target of $119.04, with 24 analysts rating the stock Buy or Strong Buy and four rating it Hold.
  • Abbott reported quarterly EPS of $1.42, matching consensus, while revenue of $13.01 billion slightly topped estimates and rose 14.5% year over year.
  • MarketBeat previews the top five stocks to own by December 1st.

Abbott Laboratories (NYSE:ABT - Get Free Report) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating in a research note issued on Thursday, FinViz reports. The brokerage currently has a $124.00 price objective on the healthcare product maker's stock. Leerink Partners's price target suggests a potential upside of 18.68% from the company's current price.

Other equities analysts have also issued research reports about the stock. Wall Street Zen raised shares of Abbott Laboratories from a "hold" rating to a "buy" rating in a report on Saturday, October 24th. Weiss Ratings raised shares of Abbott Laboratories from a "hold (c-)" rating to a "hold (c)" rating in a research note on Friday, September 18th. UBS Group cut their price objective on Abbott Laboratories from $135.00 to $125.00 and set a "buy" rating on the stock in a research report on Tuesday, July 28th. Wells Fargo & Company boosted their price target on shares of Abbott Laboratories from $112.00 to $119.00 and gave the company an "overweight" rating in a research report on Thursday, October 22nd. Finally, Rothschild & Co Redburn upgraded shares of Abbott Laboratories from a "neutral" rating to a "buy" rating and boosted their target price for the company from $119.00 to $127.00 in a report on Friday, October 2nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $119.04.

Read Our Latest Stock Analysis on Abbott Laboratories

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $104.48 on Thursday. Abbott Laboratories has a one year low of $81.97 and a one year high of $131.49. The firm has a 50-day moving average of $103.88 and a 200-day moving average of $101.71. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.45 and a quick ratio of 1.00. The company has a market cap of $180.96 billion, a P/E ratio of 38.99, a P/E/G ratio of 1.84 and a beta of 0.54.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.42. Abbott Laboratories had a net margin of 9.75% and a return on equity of 18.04%. The business had revenue of $13.01 billion during the quarter, compared to the consensus estimate of $12.99 billion. During the same quarter last year, the company posted $1.30 earnings per share. The firm's quarterly revenue was up 14.5% compared to the same quarter last year. Equities research analysts forecast that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Insider Transactions at Abbott Laboratories

In other news, EVP Mary Moreland sold 3,500 shares of the stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $116.00, for a total transaction of $406,000.00. Following the completion of the transaction, the executive vice president directly owned 100,791 shares in the company, valued at approximately $11,691,756. This represents a 3.36% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.46% of the company's stock.

Institutional Investors Weigh In On Abbott Laboratories

Several hedge funds and other institutional investors have recently modified their holdings of ABT. BlackRock Inc. grew its position in shares of Abbott Laboratories by 4.6% during the 2nd quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker's stock worth $13,843,610,000 after buying an additional 6,769,518 shares in the last quarter. State Street Corp boosted its stake in Abbott Laboratories by 0.6% in the third quarter. State Street Corp now owns 81,431,110 shares of the healthcare product maker's stock valued at $8,047,837,000 after acquiring an additional 504,876 shares in the last quarter. Bank of America Corp DE purchased a new position in Abbott Laboratories during the 2nd quarter worth $1,603,607,000. Deutsche Bank AG increased its holdings in shares of Abbott Laboratories by 18.6% during the second quarter. Deutsche Bank AG now owns 16,706,669 shares of the healthcare product maker's stock valued at $1,515,963,000 after acquiring an additional 2,614,965 shares in the last quarter. Finally, Legal & General Group Plc purchased a new position in shares of Abbott Laboratories in the second quarter worth $1,082,524,000. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Abbott Laboratories Company Profile

(Get Free Report)

Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott's offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.

Further Reading

Analyst Recommendations for Abbott Laboratories (NYSE:ABT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Abbott Laboratories Right Now?

Before you consider Abbott Laboratories, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.

While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines